COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS
Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.
1 . (canceled)
2 . A compound represented by the structure of Formula III:
wherein
X is chosen from direct bond, O, NH, and an amino acid residue;
R 4 is chosen from OH, NO, NO 2 , an amino acid residue, a fibric acid residue, guanidine, tetrazolyl, agmatine, an amino-containing compound; lower alkyl terminating in ONO, (ONO 2 ) 2 , or guanidine; a resveratrol residue; and an imidazoline receptor agonist residue;
and p is 1 to 3.
3 . (canceled)
4 . A compound according to claim 2 , by selected from the following structures:
5 - 6 . (canceled)
7 . A compound according to claim 2 , wherein X is O and R 4 is lower alkyl terminating in ONO.
8 . A compound according to claim 7 , chosen from the following structures:
9 . A compound according to claim 2 , wherein X is O and R 4 is lower alkyl terminating in (ONO 2 ) p , wherein p=1.
10 . A compound according to claim 9 , chosen from the following structures:
11 - 12 . (canceled)
13 . A compound according to claim 2 , wherein X is NH and R 4 is lower alkyl terminating in (ONO 2 ) p , wherein p=3.
14 . (canceled)
15 . A compound according to claim 2 , wherein X is NH and R 4 is lower alkyl terminating in (ONO 2 ) p , wherein p=1.
16 . A compound according to claim 2 , chosen from the following structures:
17 . A compound according to claim 2 , wherein X is NH and R 4 is lower alkyl terminating in guanidine.
18 - 19 . (canceled)
20 . A compound according to claim 2 chosen from the following structures:
21 - 22 . (canceled)
23 . A compound according to claim 2 , wherein X is an amino acid residue or a direct bond and R 4 is an amino acid residue or a lower alkyl terminating in guanidine.
24 - 27 . (canceled)
28 . A compound according to claim 23 represented by any of the following structures:
29 . A compound according to claim 2 , wherein X is O and R 4 is a resveratrol residue.
30 . A compound according to claim 29 chosen from the following structures:
(12A)
wherein R 10 is C 1 -C 6 acyl; and
wherein R 11 is C 1 -C 6 alkyl.
31 - 32 . (canceled)
33 . A compound according to claim 30 chosen from the following structures:
34 - 35 . (canceled)
36 . A compound according to claim 2 represented by any of the following structures:
37 - 74 . (canceled)
75 . A composition comprising one or more of the compound according to claim 2 and at least one lipid altering agent.
76 - 111 . (canceled)
112 . A composition according to claim 75 further comprising a therapeutically effective amount of at least one phosphodiesterase inhibitor.
113 - 121 . (canceled)
122 . A pharmaceutical composition comprising a therapeutically effective amount of at least one of the compound according to claim 2 and a pharmaceutically acceptable excipient, diluent, or carrier.
123 . (canceled)
124 . A method for treating or preventing a lipid metabolism disorder, improving lipid parameters, improving glycemic control, reducing glycosylated hemoglobin levels (HbA 1C ), lowering fasting plasma glucose (FPG) levels, reducing peak and 2-hour post-prandial glucose (PPG) levels, improving insulin sensitivity or reducing insulin resistance, increasing insulin secretion or reducing the risk of developing diabetes-associated complications, the method comprising administering to a patient in need thereof a therapeutically effective amount of one or more of the compound according to claim 2 .
125 - 149 . (canceled)